The Award Ceremony of 2021 Top 20 of Deloitte Shenzhen High-Tech High-Growth Groups and Rising Star Enterprises was successfully held On October 28 in 2021. Bemei Pharma was listed on the 2021 Shenzhen Rising Star Enterprises List.The Shenzhen Regional selection is co-sponsored by Deloitte China and Shenzhen Business Federation, aiming to discover and commend outstan...

奥维平®，whose generic name is Oseltamivir Phosphate for Oral Suspension, was formally approved by NMPA, the National Medical Products Administration recently.Oseltamivir Phosphate for Oral Suspension, as the first product forcooperation between Shenzhen Bemei Pharma and HETERO LABS LIMITED of India, its Regulatory application was officially accepted by the C...

Announcement on Acceptance of Application for Posaconazole oral suspensionGeneric name:Posaconazole oral suspensionDosage form:oral suspension Registration category:5.2 categoryBeimeiPharmaandDeva Holding A.Ş. have come to an exclusive license agreement forPosaconazole oral suspensionin December 2020. According to the agreement,BeimeiPharmais responsible for the registration and...

Always with Beimei, Always with love--Happy Children's DayGift for children on Children's Day by Center for Drug Evaluation, NMPATo further encourage research and development of children's drug, NMPA website open the "children's drug column" in the hot column on June 1, 2021, the children's drug-related policies and regulations, guidelines, train...

Announcement on Acceptance of Application for Esomeprazole magnesium for delayed release oral suspensionGeneric name:Esomeprazole magnesium for delayed-release oral suspension Dosage form:delayed-release oral suspension Registration category:5.2 categoryBeimeiPharmaandCiplaLtd. have come to an exclusive license agreement foresomeprazolemagnesium for delayed-release oral suspension in O...

"Innovator and explorer in the field of pediatric medicine in China"Bemei’s 2021 Annual Meeting was successfully concluded!It’s the season of spring, at 2:00 pm on March 5, 2021, Bemei’s 2021 Annual Meeting was held in the conference center of Kexing Science Park.Focusing on the theme of "Innovator and explorer in China's pediatric drug field", Ms. Wu G...

Shenzhen Beimei Pharma completedA roundfinancingOn 26th January 2021,Shenzhen Beimei Pharma Co., Ltd.(hereinafter referred to as "Beimei Pharma") officially announced the completion of A roundfinancing of tens of millions of RMB, invested by Sunhope Investment Group(hereinafter referred to as "Sunhope"). This round of financing will be mainly used for R&a...

Beimei Pharma and Deva Holding A.Ş. reached an exclusive license and supply agreement in China for one product that have been approved for marketing in European On December 2, 2020, Shenzhen Beimei Pharma Co., Ltd. (hereinafter referred to as "Beimei Pharma") and Deva Holding A.Ş. of Turkey (hereinafter referred to as "De...

Beimei Pharma and Ciplareached an exclusive license and supply agreementin China for two products that have been approved for marketing in the United StatesOn October 9, 2020, Shenzhen Beimei PharmaCo., Ltd. (hereinafter referred to as "Beimei Pharma") and Cipla Ltd (hereinafter referred to as "Cipla") signed an exclusive and supplyagreementin China for two p...